Candel Therapeutics (CADL) EBITDA Margin (2020 - 2022)
Candel Therapeutics' (CADL) quarterly EBITDA Margin came in at 26132.26% in Q4 2022, down 5273226.0% year-on-year from N/an in Q4 2021, and up 8.78% quarter-over-quarter from 28648.39% in Q3 2022.
Candel Therapeutics (CADL) EBITDA Margin (2020 - 2022) Analysis & Trends
Candel Therapeutics has disclosed EBITDA Margin across 3 years of filings, most recently posting 26132.26% for Q4 2022.
- EBITDA Margin for Q4 2022 came in at 26132.26%, down 5273226.0% year-over-year; the trailing twelve-month figure through Dec 2022 was 28000.81% (up 866889.0% YoY), and the FY2022 annual result was 27777.6%, up 834640.0% from the prior year.
- EBITDA Margin came in at 26132.26% for Q4 2022 at Candel Therapeutics, up from 28648.39% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 26600.0% in Q4 2021 to a low of 55096.77% in Q2 2021.
- The 3-year median for EBITDA Margin is 28235.48% (2022), against an average of 23468.91%.
- Across the five-year window, EBITDA Margin jumped 6056129 bps in 2021 and slumped 5273226 bps in 2022, its largest moves.
- Candel Therapeutics' EBITDA Margin stood at 33961.29% in 2020, then jumped by 178 bps to 26600.0% in 2021, then tumbled by 198 bps to 26132.26% in 2022.
- The last three EBITDA Margin figures came in at 26132.26% (Q4 2022), 28648.39% (Q3 2022), and 28235.48% (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Candel Therapeutics | 440.62 Mn | 440.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -26,132.26% |
| Sep 30, 2022 | -28,648.39% |
| Jun 30, 2022 | -28,235.48% |
| Mar 31, 2022 | -28,987.10% |
| Dec 31, 2021 | 26,600.00% |
| Sep 30, 2021 | -52,135.48% |
| Jun 30, 2021 | -55,096.77% |
| Mar 31, 2021 | -15,022.58% |
| Dec 31, 2020 | -33,961.29% |
| Sep 30, 2020 | -8,251.61% |
| Jun 30, 2020 | -8,287.10% |